FDA says no to safer, longer lasting, form of buprenorphine that cannot be lost, stolen, sold or accidentally ingested by children.
Imagine a form of buprenorphine which could not be lost stolen or sold, delivered a consistent daily dose (could not be overdosed or underdosed), ensured at least 6 months of medication compliance, had absolutely no risk of accidental pediatric exposure, and would still be effective at treating opioid addiction. Sounds like a miracle, or at least a major step forward, right? Not according to the FDA who earlier this year rejected such an advancement in treatment and for reasons largely unrelated to the medication’s lifesaving potential. Meanwhile, the CDC reports 45 people a day die from prescription opioid overdose.